Aethlon Medical (NASDAQ:AEMD) changed -5.50% to recent value of $1.89. The stock transacted 327185 shares during most recent day however it has an average volume of 2.57M shares. It spotted trading -72.57% off 52-week high price. On the other end, the stock has been noted 147.38% away from the low price over the last 52-weeks.

On Aug. 11, 2020, Aethlon Medical (NASDAQ:AEMD) a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, revealed financial results for its first quarter ended June 30, 2020.

Financial Results for the First Quarter Ended June 30, 2020

At June 30, 2020, we had a cash balance of approximately $15.7 million.

Operating expenses for the three months ended June 30, 2020 were approximately $1.4 million, compared to approximately $1.6 million for the three months ended June 30, 2019. This decrease of approximately $200,000, or 12%, in the 2020 period was due to a decrease in payroll and related expenses of approximately $170,000 and in professional fees of approximately $43,000, which was partially offset by an increase in general and administrative expenses of approximately $27,000.

The $170,000 decrease in payroll and related expenses was due to the combination of a $242,000 reduction in stock-based compensation expense and a $73,000 increase in our cash-based compensation expense. The cash-based compensation increase was in turn due to additions to our headcount and to salary increases.

The $43,000 decrease in our professional fees was primarily due to a $22,000 decrease in our legal fees and a $22,000 decrease in our accounting fees.

The $27,000 increase in general and administrative expenses was primarily due a $26,000 increase in our clinical trial expenses as we prepare for our planned clinical trials.

Its earnings per share (EPS) expected to touch remained 63.60% for this year.

The company has 12.07M of outstanding shares and 11.79M shares were floated in the market. According to the most recent quarter its current ratio was 9.4 that represents company’s ability to meet its current financial obligations. The price moved ahead of -7.78% from the mean of 20 days, -0.17% from mean of 50 days SMA and performed -11.29% from mean of 200 days price. Company’s performance for the week was -10.85%, 6.78% for month and YTD performance remained 96.26%.